Fanconi Anemia - Pipeline Review, H1 2016 Summary Global Markets Direct's, 'Fanconi Anemia - Pipeline Review, H1 2016', provides an overview of the Fanconi Anemia pipeline landscape. The report provides comprehensive information on the therapeutics under development for Fanconi Anemia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Fanconi Anemia and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Fanconi Anemia - The report reviews pipeline therapeutics for Fanconi Anemia by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Fanconi Anemia therapeutics and enlists all their major and minor projects - The report assesses Fanconi Anemia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Fanconi Anemia Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Fanconi Anemia - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Fanconi Anemia pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Fanconi Anemia Overview 6 Therapeutics Development 7 Pipeline Products for Fanconi Anemia - Overview 7 Pipeline Products for Fanconi Anemia - Comparative Analysis 8 Fanconi Anemia - Therapeutics under Development by Companies 9 Fanconi Anemia - Therapeutics under Investigation by Universities/Institutes 10 Fanconi Anemia - Pipeline Products Glance 11 Clinical Stage Products 11 Early Stage Products 12 Fanconi Anemia - Products under Development by Companies 13 Fanconi Anemia - Products under Investigation by Universities/Institutes 14 Fanconi Anemia - Companies Involved in Therapeutics Development 15 Abeona Therapeutics, Inc. 15 Genethon 16 Fanconi Anemia - Therapeutics Assessment 17 Assessment by Monotherapy Products 17 Assessment by Target 18 Assessment by Mechanism of Action 20 Assessment by Route of Administration 22 Assessment by Molecule Type 24 Drug Profiles 26 ABO-301 - Drug Profile 26 Product Description 26 Mechanism of Action 26 R&D Progress 26 AD-6626 - Drug Profile 27 Product Description 27 Mechanism of Action 27 R&D Progress 27 Cell Therapy to Activate FANC-A for Fanconi Anemia - Drug Profile 28 Product Description 28 Mechanism of Action 28 R&D Progress 28 JP4-039 - Drug Profile 29 Product Description 29 Mechanism of Action 29 R&D Progress 29 Stem Cell Therapy to Activate FANCA Protein for Fanconi Anemia - Drug Profile 31 Product Description 31 Mechanism of Action 31 R&D Progress 31 Stem Cell Therapy to Activate FANCA Protein for Fanconi Anemia - Drug Profile 32 Product Description 32 Mechanism of Action 32 R&D Progress 32 Stem Cell Therapy to Activate FANCA Protein for Fanconi Anemia - Drug Profile 33 Product Description 33 Mechanism of Action 33 R&D Progress 33 Fanconi Anemia - Recent Pipeline Updates 34 Fanconi Anemia - Dormant Projects 35 Fanconi Anemia - Product Development Milestones 36 Featured News & Press Releases 36 Feb 24, 2016: Abeona Therapeutics to Present on CRISPR/CAS9 Technology Platform Progress at CRISPR Precision Gene Editing Congress 36 Oct 03, 2011: Experimental Drug Could Help Protect Some Cancer Patients From Radiation Side Effects, UPCI Researchers Find 36 Appendix 38 Methodology 38 Coverage 38 Secondary Research 38 Primary Research 38 Expert Panel Validation 38 Contact Us 38 Disclaimer 39
List of Tables
Number of Products under Development for Fanconi Anemia, H1 2016 7 Number of Products under Development for Fanconi Anemia - Comparative Analysis, H1 2016 8 Number of Products under Development by Companies, H1 2016 9 Number of Products under Investigation by Universities/Institutes, H1 2016 10 Comparative Analysis by Clinical Stage Development, H1 2016 11 Comparative Analysis by Early Stage Development, H1 2016 12 Products under Development by Companies, H1 2016 13 Products under Investigation by Universities/Institutes, H1 2016 14 Fanconi Anemia - Pipeline by Abeona Therapeutics, Inc. , H1 2016 15 Fanconi Anemia - Pipeline by Genethon, H1 2016 16 Assessment by Monotherapy Products, H1 2016 17 Number of Products by Stage and Target, H1 2016 19 Number of Products by Stage and Mechanism of Action, H1 2016 21 Number of Products by Stage and Route of Administration, H1 2016 23 Number of Products by Stage and Molecule Type, H1 2016 25 Fanconi Anemia Therapeutics - Recent Pipeline Updates, H1 2016 34 Fanconi Anemia - Dormant Projects, H1 2016 35
List of Figures
Number of Products under Development for Fanconi Anemia, H1 2016 7 Number of Products under Development for Fanconi Anemia - Comparative Analysis, H1 2016 8 Number of Products under Development by Companies, H1 2016 9 Number of Products under Investigation by Universities/Institutes, H1 2016 10 Comparative Analysis by Clinical Stage Development, H1 2016 11 Comparative Analysis by Early Stage Products, H1 2016 12 Assessment by Monotherapy Products, H1 2016 17 Number of Products by Targets, H1 2016 18 Number of Products by Stage and Targets, H1 2016 18 Number of Products by Mechanism of Actions, H1 2016 20 Number of Products by Stage and Mechanism of Actions, H1 2016 20 Number of Products by Routes of Administration, H1 2016 22 Number of Products by Stage and Routes of Administration, H1 2016 22 Number of Products by Molecule Types, H1 2016 24 Number of Products by Stage and Molecule Types, H1 2016 24
Global contact lenses market size is estimated to reach USD 12.5 billion by 2020, according to a new industry report by Radiant Insights, Inc. Growing number of ophthalmic disorder observed in global population especially children is likely to driveRead More...
Global LCP (Liquid Crystal Polymer) industry is forecasted to reach USD 1.23 billion by 2020, as per a new research report by Radiant Insights, Inc. Growing trend towards developing militarized components and connectors are likely to drive the demandRead More...
Global geotextile market size is likely to be valued at USD 8.24 billion by 2020; as per a new research report by Radiant Insights, Inc. Increasing use in soil reinforcement activity coupled with growing application scope in road & railway developmenRead More...
Global gold nanoparticles market size is expected to reach 4.99 billion by 2020, witnessing gains at a CAGR of 24.7%. Positive outlook towards the increasing applications of nanotechnology in medical and dentistry such as drug delivery systems, nanomRead More...
Europe industrial air filtration market size is projected to reach USD 1,690.8 million by 2020, as per a new research report by Radiant Insights, Inc. Increasing implementation in various industries such as metal, cement and food & beverages among otRead More...
Get your queries resolved from an industry expert. Request for a free product review before report purchase.
Toll Free: 1-888-928-9744
Email: [email protected]
Speak to the report author to design an exclusive study to serve your research needs.
A testimonial for service excellence represented in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.